Literature DB >> 27292772

Functional roles of CSPG4/NG2 in chondrosarcoma.

Nuor S M Jamil1, Asim Azfer1, Harrison Worrell1, Donald M Salter1.   

Abstract

CSPG4/NG2 is a multifunctional transmembrane protein with limited distribution in adult tissues including articular cartilage. The purpose of this study was to investigate the possible roles of CSPG4/NG2 in chondrosarcomas and to establish whether this molecule may have potential for targeted therapy. Stable knock-down of CSPG4/NG2 in the JJ012 chondrosarcoma cell line by shRNA resulted in decreased cell proliferation and migration as well as a decrease in gene expression of the MMP (matrix metalloproteinase) 3 protease and ADAMTS4 (aggrecanase). Chondrosarcoma cells in which CSPG4/NG2 was knocked down were more sensitive to doxorubicin than wild-type cells. The results indicate that CSPG4/NG2 has roles in regulating chondrosarcoma cell function in relation to growth, spread and resistance to chemotherapy and that anti-CSPG4/NG2 therapies may have potential in the treatment of surgically unresectable chondrosarcoma.
© 2016 The Authors. International Journal of Experimental Pathology © 2016 International Journal of Experimental Pathology.

Entities:  

Keywords:  CSPG4; NG2; chondrosarcoma; therapy

Mesh:

Substances:

Year:  2016        PMID: 27292772      PMCID: PMC4926050          DOI: 10.1111/iep.12189

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  43 in total

1.  Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading.

Authors:  H L Evans; A G Ayala; M M Romsdahl
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

2.  High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan.

Authors:  L Goretzki; M A Burg; K A Grako; W B Stallcup
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

3.  Chondrosarcoma of bone: an oncological and functional follow-up study.

Authors:  J Bruns; M Elbracht; O Niggemeyer
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

4.  Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility.

Authors:  Irwan T Makagiansar; Scott Williams; Kimberlee Dahlin-Huppe; Jun-ichi Fukushi; Tomas Mustelin; William B Stallcup
Journal:  J Biol Chem       Date:  2004-10-25       Impact factor: 5.157

5.  Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.

Authors:  A Mittelman; Z J Chen; C C Liu; S Hirai; S Ferrone
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Shedding of NG2 by MMP-13 attenuates anoikis.

Authors:  Nam E Joo; Di Miao; Mercedes Bermúdez; William B Stallcup; Yvonne L Kapila
Journal:  DNA Cell Biol       Date:  2014-12       Impact factor: 3.311

7.  NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin.

Authors:  Jun-ichi Fukushi; Irwan T Makagiansar; William B Stallcup
Journal:  Mol Biol Cell       Date:  2004-06-04       Impact factor: 4.138

8.  NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients.

Authors:  Maria Serena Benassi; Laura Pazzaglia; Antonella Chiechi; Marco Alberghini; Amalia Conti; Sabrina Cattaruzza; Bruna Wassermann; Piero Picci; Roberto Perris
Journal:  J Orthop Res       Date:  2009-01       Impact factor: 3.494

9.  The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.

Authors:  M Chekenya; C Krakstad; A Svendsen; I A Netland; V Staalesen; B B Tysnes; F Selheim; J Wang; P Ø Sakariassen; T Sandal; P E Lønning; T Flatmark; P Ø Enger; R Bjerkvig; M Sioud; W B Stallcup
Journal:  Oncogene       Date:  2008-05-12       Impact factor: 9.867

Review 10.  Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Authors:  Xing Dai; Wei Ma; Xijing He; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2011-08
View more
  3 in total

Review 1.  CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.

Authors:  Sandra Jordaan; Shivan Chetty; Neelakshi Mungra; Iris Koopmans; Peter E van Bommel; Wijnand Helfrich; Stefan Barth
Journal:  Biomedicines       Date:  2017-06-28

2.  Neuron/Glial Antigen 2-Type VI Collagen Interactions During Murine Temporomandibular Joint Osteoarthritis.

Authors:  Mamoru Yotsuya; Andrew E Bertagna; Nageeb Hasan; Scott Bicknell; Toru Sato; David A Reed
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

3.  Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.

Authors:  Sjoerd P F T Nota; David O Osei-Hwedieh; David L Drum; Xinhui Wang; Francesco Sabbatino; Soldano Ferrone; Joseph H Schwab
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.